These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18425336

  • 41. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [Abstract] [Full Text] [Related]

  • 42. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y.
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
    [Abstract] [Full Text] [Related]

  • 43. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
    Wang Y, Chen J, Li X, He Y, Hu B, Ji C, Xu J.
    Oncol Rep; 2011 Apr; 25(4):1047-52. PubMed ID: 21286668
    [Abstract] [Full Text] [Related]

  • 44. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
    Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E, Spanish Group for the Treatment of Digestive Tumours.
    Eur J Cancer; 2008 Jun; 44(9):1229-37. PubMed ID: 18448328
    [Abstract] [Full Text] [Related]

  • 45. [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].
    Moldvay J, Pápay J, Puskás R, Furák J, Losonczy G, Matolcsy A.
    Magy Onkol; 2011 Jun; 55(2):105-9. PubMed ID: 21655476
    [Abstract] [Full Text] [Related]

  • 46. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
    Boku N, Ohtsu A, Nagashima F, Shirao K, Koizumi W.
    Jpn J Clin Oncol; 2007 Jul; 37(7):509-14. PubMed ID: 17673469
    [Abstract] [Full Text] [Related]

  • 47. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 48. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.
    Park JS, Jeon EK, Chun SH, Won HS, Lee A, Hur SY, Lee KH, Bae SN, Yoon SC, Hong SH.
    Gynecol Oncol; 2011 Feb; 120(2):275-9. PubMed ID: 21093896
    [Abstract] [Full Text] [Related]

  • 49. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK.
    Br J Cancer; 2011 Mar 29; 104(7):1126-34. PubMed ID: 21364592
    [Abstract] [Full Text] [Related]

  • 50. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
    Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN.
    Anticancer Res; 2010 Oct 29; 30(10):4289-95. PubMed ID: 21036754
    [Abstract] [Full Text] [Related]

  • 51. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.
    Gynecol Oncol; 2013 Aug 29; 130(2):377-82. PubMed ID: 23632208
    [Abstract] [Full Text] [Related]

  • 52. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov 29; 48(11):847-52. PubMed ID: 24444563
    [Abstract] [Full Text] [Related]

  • 53. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH, Do IG, Kim HS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Kwon GY, Lim HY.
    APMIS; 2010 Dec 29; 118(12):941-8. PubMed ID: 21091775
    [Abstract] [Full Text] [Related]

  • 54. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ, Cho SH, Yoon JY, Hwang JE, Bae WK, Shim HJ, Chung IJ.
    Cancer Chemother Pharmacol; 2009 Dec 29; 65(1):159-66. PubMed ID: 19479256
    [Abstract] [Full Text] [Related]

  • 55. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
    Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.
    Eur J Cancer; 2008 Jan 29; 44(1):54-60. PubMed ID: 17976974
    [Abstract] [Full Text] [Related]

  • 56. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK.
    World J Gastroenterol; 2008 Nov 07; 14(41):6401-7. PubMed ID: 19009659
    [Abstract] [Full Text] [Related]

  • 57. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araújo AP, Lopes C, Medeiros R.
    Biochem Biophys Res Commun; 2006 Feb 03; 340(1):256-62. PubMed ID: 16364249
    [Abstract] [Full Text] [Related]

  • 58. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.
    Int J Oncol; 2008 Dec 03; 33(6):1257-62. PubMed ID: 19020759
    [Abstract] [Full Text] [Related]

  • 59. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y, Tong C.
    J Cancer Res Clin Oncol; 2012 Feb 03; 138(2):231-8. PubMed ID: 22102173
    [Abstract] [Full Text] [Related]

  • 60. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2008 Feb 03; 18(4):702-10. PubMed ID: 17961161
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.